Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240].
Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, Kiani FK, Asl SH, Atyabi F, Hassannia H, Hojjat-Farsangi M, Namdar A, Ghalamfarsa G, Jadidi-Niaragh F. Masjedi A, et al. Among authors: namdar a. Nanomedicine. 2023 Jul;51:102690. doi: 10.1016/j.nano.2023.102690. Epub 2023 May 9. Nanomedicine. 2023. PMID: 37167816 No abstract available.
Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
Kheshtchin N, Arab S, Ajami M, Mirzaei R, Ashourpour M, Mousavi N, Khosravianfar N, Jadidi-Niaragh F, Namdar A, Noorbakhsh F, Hadjati J. Kheshtchin N, et al. Among authors: namdar a. Cancer Immunol Immunother. 2016 Oct;65(10):1159-67. doi: 10.1007/s00262-016-1879-5. Epub 2016 Aug 6. Cancer Immunol Immunother. 2016. PMID: 27497816 Free PMC article.
Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway.
Masjedi A, Hassannia H, Atyabi F, Rastegari A, Hojjat-Farsangi M, Namdar A, Soleimanpour H, Azizi G, Nikkhoo A, Ghalamfarsa G, Mirshafiey A, Jadidi-Niaragh F. Masjedi A, et al. Among authors: namdar a. Int J Biol Macromol. 2019 Jul 15;133:436-445. doi: 10.1016/j.ijbiomac.2019.03.223. Epub 2019 Mar 30. Int J Biol Macromol. 2019. PMID: 30936011
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer.
Karpisheh V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, Yousefi B, Jadidi-Niaragh F. Karpisheh V, et al. Among authors: namdar a. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106338. doi: 10.1016/j.prostaglandins.2019.106338. Epub 2019 May 15. Prostaglandins Other Lipid Mediat. 2019. PMID: 31100474 Review.
Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H, Ghasemi Chaleshtari M, Atyabi F, Nosouhian M, Masjedi A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Ghalamfarsa G, Sabz G, Hasanzadeh S, Yousefi M, Jadidi-Niaragh F. Hassannia H, et al. Among authors: namdar a. Immunology. 2020 Jan;159(1):75-87. doi: 10.1111/imm.13126. Epub 2019 Oct 24. Immunology. 2020. PMID: 31587253 Free PMC article.
Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
Hashemi V, Maleki LA, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, Yousefi M, Yousefi B, Jadidi-Niaragh F. Hashemi V, et al. Among authors: namdar a. Int Immunopharmacol. 2020 Jan;78:106087. doi: 10.1016/j.intimp.2019.106087. Epub 2019 Dec 13. Int Immunopharmacol. 2020. PMID: 31841758 Review.
CDK1 in Breast Cancer: Implications for Theranostic Potential.
Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Yousefi M, Jadidi-Niaragh F. Izadi S, et al. Among authors: namdar a. Anticancer Agents Med Chem. 2020;20(7):758-767. doi: 10.2174/1871520620666200203125712. Anticancer Agents Med Chem. 2020. PMID: 32013835 Review.
63 results